[go: up one dir, main page]

ES2146555B1 - USE OF FORMULATIONS BASED ON HYDRO-Soluble FRACTIONS OF PHLEBODIUM DECUMANUM (EXPLY-37) AND / OR POLYPODIUM LEUCOTOMOS AS A NUTRITIONAL COMPLEMENT IN THE PREVENTION AND REVERSION OF THE PHYSICAL ENVELOPE SYNDROME. - Google Patents

USE OF FORMULATIONS BASED ON HYDRO-Soluble FRACTIONS OF PHLEBODIUM DECUMANUM (EXPLY-37) AND / OR POLYPODIUM LEUCOTOMOS AS A NUTRITIONAL COMPLEMENT IN THE PREVENTION AND REVERSION OF THE PHYSICAL ENVELOPE SYNDROME.

Info

Publication number
ES2146555B1
ES2146555B1 ES009900133A ES9900133A ES2146555B1 ES 2146555 B1 ES2146555 B1 ES 2146555B1 ES 009900133 A ES009900133 A ES 009900133A ES 9900133 A ES9900133 A ES 9900133A ES 2146555 B1 ES2146555 B1 ES 2146555B1
Authority
ES
Spain
Prior art keywords
exply
decumanum
polypodium leucotomos
syndrome
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES009900133A
Other languages
Spanish (es)
Other versions
ES2146555A1 (en
Inventor
Ferrer Miguel Yesares
Teresa Galvan Carlos De
Garcia Antonio Alcaide
Morillas Miguel Enriqu Yesares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HELECHOS INTERNACIONALES HONDU
Helsint SAL
Original Assignee
HELECHOS INTERNACIONALES HONDU
Helsint SAL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HELECHOS INTERNACIONALES HONDU, Helsint SAL filed Critical HELECHOS INTERNACIONALES HONDU
Priority to ES009900133A priority Critical patent/ES2146555B1/en
Priority to PCT/ES2000/000021 priority patent/WO2000043022A1/en
Publication of ES2146555A1 publication Critical patent/ES2146555A1/en
Application granted granted Critical
Publication of ES2146555B1 publication Critical patent/ES2146555B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Empleo de formulaciones a base de fracciones hidrosolubles de Phlebodium decumanum (EXPLY-37) y/o Polypodium leucotomos como complemento nutricional en la prevención y reversión del síndrome de sobreesfuerzo físico. Las formulaciones pueden comprender fracciones hidrosolubles de fronde y rizoma de las variedades de Plhebodium decumanum (EXPLY-37) y/o Polypodium leucotomos cultivadas en la plantación de HELSINT, S.A.L. próxima al lago Yojoa (Honduras), junto con, opcionalmente, rizoma de Plhebodium decumanum y/o Polypodium leucotomos y uno o varios componentes aminoácidos. Estas formulaciones mejoran la resistencia y potencia física, restauran y mantienen el equilibrio inmunológico evitando la aparición de infecciones oportunistas, protegen en condiciones extremas de esfuerzo de la extenuación y del daño usular, especialmente en lesiones óseas, musculares y cartilaginosas y reducen el tiempo de curación cuando tales lesiones se han producido.Use of formulations based on water-soluble fractions of Phlebodium decumanum (EXPLY-37) and / or Polypodium leucotomos as nutritional supplement in the prevention and reversal of physical overexertion syndrome. The formulations may comprise water-soluble frond and rhizome fractions of the varieties of Plhebodium decumanum (EXPLY-37) and / or Polypodium leucotomos grown in the plantation of HELSINT, S.A.L. next to Lake Yojoa (Honduras), together with, optionally, rhizome of Plhebodium decumanum and / or Polypodium leucotomos and one or several amino acid components. These formulations improve endurance and physical potency, restore and maintain the immune balance avoiding the appearance of opportunistic infections, protect under extreme stress conditions from exhaustion and usular damage, especially in bone, muscle and cartilaginous lesions and reduce healing time. when such injuries have occurred.

ES009900133A 1999-01-22 1999-01-22 USE OF FORMULATIONS BASED ON HYDRO-Soluble FRACTIONS OF PHLEBODIUM DECUMANUM (EXPLY-37) AND / OR POLYPODIUM LEUCOTOMOS AS A NUTRITIONAL COMPLEMENT IN THE PREVENTION AND REVERSION OF THE PHYSICAL ENVELOPE SYNDROME. Expired - Fee Related ES2146555B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ES009900133A ES2146555B1 (en) 1999-01-22 1999-01-22 USE OF FORMULATIONS BASED ON HYDRO-Soluble FRACTIONS OF PHLEBODIUM DECUMANUM (EXPLY-37) AND / OR POLYPODIUM LEUCOTOMOS AS A NUTRITIONAL COMPLEMENT IN THE PREVENTION AND REVERSION OF THE PHYSICAL ENVELOPE SYNDROME.
PCT/ES2000/000021 WO2000043022A1 (en) 1999-01-22 2000-01-20 Utilization of formulations based on water-soluble fractions of phlebodium decumanum(exply-37) and polypodium leucotomos as nutritional supplement in the prevention and reversion of excessive physical effort syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009900133A ES2146555B1 (en) 1999-01-22 1999-01-22 USE OF FORMULATIONS BASED ON HYDRO-Soluble FRACTIONS OF PHLEBODIUM DECUMANUM (EXPLY-37) AND / OR POLYPODIUM LEUCOTOMOS AS A NUTRITIONAL COMPLEMENT IN THE PREVENTION AND REVERSION OF THE PHYSICAL ENVELOPE SYNDROME.

Publications (2)

Publication Number Publication Date
ES2146555A1 ES2146555A1 (en) 2000-08-01
ES2146555B1 true ES2146555B1 (en) 2001-03-01

Family

ID=8307037

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009900133A Expired - Fee Related ES2146555B1 (en) 1999-01-22 1999-01-22 USE OF FORMULATIONS BASED ON HYDRO-Soluble FRACTIONS OF PHLEBODIUM DECUMANUM (EXPLY-37) AND / OR POLYPODIUM LEUCOTOMOS AS A NUTRITIONAL COMPLEMENT IN THE PREVENTION AND REVERSION OF THE PHYSICAL ENVELOPE SYNDROME.

Country Status (2)

Country Link
ES (1) ES2146555B1 (en)
WO (1) WO2000043022A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306173B1 (en) 1999-07-23 2001-05-30 Sigma Tau Healthscience Spa COMPOSITION FOR THE PREVENTION OF MUSCLE FATIGUE AND TO IMPROVE THE MUSCLE ENERGY PERFORMANCE.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES490293A0 (en) * 1980-04-02 1981-04-16 Conrad Ltd A PROCEDURE FOR OBTAINING AN EXTRACT OF THE POLAR FRACTION-NES OF THE FERNANDS OF THE POLYPODIACEAE FAMILY.
EP0503208A1 (en) * 1991-03-08 1992-09-16 Maracuyama International, S.A. Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns
ES2068163B1 (en) * 1994-05-06 1995-09-01 Esp Farmaceuticas Centrum Sa PROCEDURE FOR OBTAINING A PLANT EXTRACT WITH ACTIVITY IN THE TREATMENT OF COGNITIVE DYSFUNCTIONS AND / OR NEUROINMUNES.
ES2088770B1 (en) * 1995-02-23 1997-03-16 Esp Farmaceuticas Centrum Sa A PHARMACEUTICAL COMPOSITION WITH ACTIVITY IN THE TREATMENT OF COGNITIVE DYSFUNCTIONS AND / OR NEUROINMUNES.
IT1291127B1 (en) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti FOOD SUPPLEMENT FOR SUBJECTS DEDICATED TO INTENSE AND PROLONGED PHYSICAL ACTIVITY

Also Published As

Publication number Publication date
WO2000043022A1 (en) 2000-07-27
ES2146555A1 (en) 2000-08-01

Similar Documents

Publication Publication Date Title
JP2002504491A5 (en)
WO2004043474A3 (en) Use of one or more elements from the group containing yttrium, neodymium and zirconium
ES2190195T3 (en) USE OF AT LEAST A PROTEIC EXTRACT OF GRAIN GRAINS FROM GENDER MORINGA AND COSMETIC AND / OR PHARMACEUTICAL COMPOSITION CORRESPONDING.
CA2336542A1 (en) Extracts of zanthoxylum bungeanum, pharmaceutical and cosmetic formulations containing them
ES2091906T3 (en) COMPOSITIONS INCLUDING DERIVATIVES OF AN OMEGA-CONOTOXIN PEPTIDE AND ITS USE IN THE TREATMENT OF NEURONAL DAMAGE RELATED TO ISCHEMIA.
SG73401A1 (en) Taxanes having alkoxy alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing the same
ES2180279T3 (en) IRON-DEXTRAN COMPOSITE FOR USE AS A COMPONENT IN THERAPEUTIC COMPOSITION FOR PROFILAXIS OR IRON DEFICIENCY TREATMENT, PROCEDURE FOR THEIR PRODUCTION AND USE OF THE SAME FOR PREPARATION OF ADMINISTRABLE THERAPEUTIC COMPOSITION BY PARENTERAL ROUTE.
MX2022001719A (en) Formulations of benzazepine conjugates and uses thereof.
AU8180001A (en) Human growth hormone to stimulate mobilization of pluripotent hematopoietic stemcells
EA199800754A1 (en) ANTIPATOGENIC PEPTIDES AND COMPOSITIONS INCLUDING THEM
MD2550C2 (en) Antibiotic preparation with slow release of the active ingredient and use thereof
DE60335647D1 (en) PYRROLOQUINOLINE QUINONE AND A BETABLOCKER FOR THE TREATMENT OF ISCHEMIA OR REPERFUSION DAMAGE
ATE423848T1 (en) TRIGGER RECEPTOR INVOLVED IN THE NATURAL CYTOTOXICITY OF HUMAN NATURAL KILLER CELLS AND ANTIBODIES THAT IDENTIFY THIS RECEPTOR
ES2146555B1 (en) USE OF FORMULATIONS BASED ON HYDRO-Soluble FRACTIONS OF PHLEBODIUM DECUMANUM (EXPLY-37) AND / OR POLYPODIUM LEUCOTOMOS AS A NUTRITIONAL COMPLEMENT IN THE PREVENTION AND REVERSION OF THE PHYSICAL ENVELOPE SYNDROME.
WO2001081372A3 (en) Vancomycin analogs
MXPA05008384A (en) Cosmetic eye-care compositions comprising a low molecular weight cationic copolymer.
WO2024030856A3 (en) Immunomodulatory proteins and related methods
Ehara Description of a new species of Tuckerella from Japan (Acarina: Tuckerellidae)
RU99105659A (en) RASTOSPIR MEDICINATOR, HEPATOPROTECTIVE, IMMUNOMODULATING AND ANTIOXIDANT ACTION AND BIOLOGICALLY ACTIVE ADDITION ON THE BASIS
MXPA04005033A (en) Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes.
ATE481976T1 (en) COMPOSITIONS OF ORGANIC EXTRACTS OF GEUM JAPONICUM THUNB VAR. AND THEIR USE
AU2003208197A8 (en) Use of soluble fgl2 as an immunosuppressant
MXPA05014012A (en) Pharmaceutical compositions comprising peranhydrocyclodextrin.
RU2008128253A (en) FITOCHAI
GB9923023D0 (en) Hair care composition

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20000801

Kind code of ref document: A1

Effective date: 20000801

FD2A Announcement of lapse in spain

Effective date: 20180807